News | June 12, 2022
Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Tislelizumab is now approved in nine indications in China
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Based on a post hoc analysis, fewer required respiratory interventions
States have an important role in ensuring food safety and healthy food practices.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
To address the preventive & primary healthcare delivery gaps in India
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Subscribe To Our Newsletter & Stay Updated
